Health-Related Quality of Life in a Real-World Cohort of Patients with Advanced Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors
Oncology · 2025
DOI: 10.1159/000543541 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncology, 2025. Verfasst von Takahito Negishi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, NHO Kyushu Cancer Center, Fukuoka, Japan. Hauptthemen laut MEDLINE: Quality of Life, Immune Checkpoint Inhibitors, Carcinoma, Transitional Cell, Urologic Neoplasms. Die Arbeit nennt 23 Literaturangaben.
Abstract (Originalsprache)
Introduction
Health-related quality of life (HRQOL) has been reported in clinical trials of pembrolizumab and avelumab treatment of locally advanced or metastatic urothelial carcinoma. However, few studies have investigated the effect of immune checkpoint inhibitors (ICIs) on HRQOL in patients with urothelial carcinoma in a real-world setting.
Methods
We included 44 patients with advanced urothelial cancer who were treated with pembrolizumab or avelumab from January 2018 to November 2023. When patients visited our hospital for treatment, we evaluated their HRQOL using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 15-Palliative Care. We retrospectively reviewed the interview sheets.
Results
The median time to deterioration in global health status was 19.1 weeks. The mean scores of emotional functioning were improved in weeks 18 and 36 compared with baseline. The mean scores for fatigue and appetite loss were also improved in weeks 18 and 36.
Conclusion
ICI treatment for advanced urothelial carcinoma did not worsen HRQOL over time in a real-world setting. Tolerability of ICIs for advanced urothelial carcinoma appears good in those who received long-term treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, NHO Kyushu Cancer Center, Fukuoka, Japan.
Zitieren
APA
Negishi, T., Kobayashi, H., Furubayashi, N., Morihara, K., Nakamura, M., & Negishi, T. (2025). Health-Related Quality of Life in a Real-World Cohort of Patients with Advanced Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors. Oncology. https://doi.org/10.1159/000543541
Vancouver
Negishi T, Kobayashi H, Furubayashi N, Morihara K, Nakamura M, Negishi T. Health-Related Quality of Life in a Real-World Cohort of Patients with Advanced Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors. Oncology. 2025. doi:10.1159/000543541
BibTeX
@article{Negishi2025,
author = {Negishi, Takahito and Kobayashi, Hiroki and Furubayashi, Nobuki and Morihara, Kaede and Nakamura, Motonobu and Negishi, Takahito},
title = {Health-Related Quality of Life in a Real-World Cohort of Patients with Advanced Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors},
journal = {Oncology},
year = {2025},
doi = {10.1159/000543541}
}
EUVIMED